Drugs / Autologous Hematopoietic Stem Cell
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03113162 | May 2015 → May 2020 | multiple sclerosis | Makati Medical Center | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06589089 | Oct 2024 → Aug 2025 overdue | diffuse large B-cell lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous hematopoietic stem cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06589089 ↗ |
| Modality | Cell therapy | “autologous hematopoetic stem cell transplantation” NCT03113162 ↗ |